ERBB2 and neoplasm: Therefore, in considering the clinical importance of low HER2-trogocytosis, we suggest that HER2+ breast cancer patients whose tumor HER2 immunohistochemistry score is 3+ or 2+ might actually have a low quantity of HER2 protein.